TP53 and acute myeloid leukemia: In sum, the initial attempts to exploit the preclinical data in support of targeting the MDM2–p53 interaction or the ubiquitin–proteosome system to modulate p53 protein activity have been discouraging, but subsequent iterations guided by improved biomarkers and agents may still hold promise for TP53m-AML.